Table 4.
Multivariate analyses of risk factors for grades C-D AGVHD
| Variable | SD |
URD |
||||||
|---|---|---|---|---|---|---|---|---|
| n | OR | 95% CI | P | n | OR | 95% CI | P | |
| Treatment category | .03 | .04 | ||||||
| 1: MA+TBI+PBSC | 709 | 1.0 | 534 | 1.00 | ||||
| 2: MA + TBI + BM | 245 | 0.90 | 0.62-1.32 | .60 | 733 | 0.79 | 0.62-1.00 | .05 |
| 3: MA + nonTBI + PBSC | 1017 | 1.03 | 0.81-1.32 | .79 | 350 | 0.92 | 0.68-1.23 | .56 |
| 4: MA + nonTBI + BM | 492 | 0.61 | 0.44-0.85 | .003 | 265 | 0.67 | 0.48-0.93 | .02 |
| 5: RIC + PBSC | 622 | 1.00 | 0.76-1.31 | .98 | 405 | 0.85 | 0.64-1.12 | .25 |
| 6: RIC + BM | 67 | 0.88 | 0.46-1.70 | .71 | 83 | 0.48 | 0.28-0.83 | .009 |
| GVHD prophylaxis | .0003 | |||||||
| CSA + MTX ± other | 2645 | 1.00 | ||||||
| Tacrolimus ± MTX ± other | 484 | 0.56 | 0.42-0.75 | < .0001 | ||||
| Other | 23 | 0.59 | 0.17-1.99 | .39 | ||||
| Disease status at transplant | .01 | |||||||
| Early | 1750 | 1.00 | ||||||
| Intermediate | 520 | 1.02 | 0.78-1.32 | .90 | ||||
| Advanced | 666 | 1.32 | 1.05-1.66 | .02 | ||||
| Unknown | 216 | 1.55 | 1.10-2.18 | .01 | ||||
| Sex mismatch (D/R) | .009 | |||||||
| M/M, M/F, F/F | 2397 | 1.00 | ||||||
| F/M | 746 | 1.37 | 1.12-1.69 | .002 | ||||
| Missing | 9 | 0.62 | 0.08-5.06 | .66 | ||||
| Disease | .003 | |||||||
| ALL | 446 | 1.00 | ||||||
| AML | 1044 | 1.01 | 0.78-1.29 | .97 | ||||
| CML | 463 | 1.52 | 1.14-2.01 | .004 | ||||
| MDS | 417 | 1.25 | 0.93-1.70 | .15 | ||||
| HLA match | .0006 | |||||||
| 8/8 matched | 1532 | 1.00 | ||||||
| 7/8 matched | 614 | 1.36 | 1.12-1.66 | .002 | ||||
| ≤ 6/8 matched | 224 | 1.55 | 1.16-2.08 | .003 | ||||
Pairwise comparisons significant for the treatment categories were as follows for SD, none; and for URD, treatment category 3 versus treatment category 6 (P = .02).
CSA indicates cyclosporine; MTX, methotrexate; D, donor; R, recipient; M, male; F, female; MDS, myelodysplastic syndrome; and MA, myeloablative.